Novavax: A Profile and a Comment. See Also: Why We Need More Firms to Develop Coronavirus Vaccines

Novavax Still Rallying After Grant

The Grant That Continues To Rally the Stock

Novavax (NVAX) stock continues its ascent following yesterday’s announcement that the firm was granted up to $384 million by the coalition for Epidemic Preparedness innovation.

We remind that the grant is to help the advancement in the clinical development of the firm’s SARS-CoV-2 (COVID-19) vaccine and of scaling-up manufacturing.

We have to note that promising news for Novavax does not mean bad news for Moderna (MRNA). Many successful vaccine developments are needed against the novel coronavirus (COVID-19) by as many companies as possible in order to stop the pandemic. It’s the only possible way to defeat this silent unseen enemy of humanity.

So why Novavax?  

Leave a Reply